All In Biotech

Drug Trial Radar · NCT05014685

PPI-amoxicillin for H. Pylori Treatment

Proton Pump Inhibitor and Amoxicillin Combined Bismuth or Metronidazole for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 732 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

732

Planned (sponsor's estimate)

Start

Aug 20, 2021

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled clinical trial will identify the additional benefit of bismuth or metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • RabeprazoleDrug

    20mg bid

  • Bismuth potassium citrateDrug

    0.6g bid

  • MetronidazoleDrug

    0.4g tid

  • AmoxicillinDrug

    1g tid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rate of Helicobacter pyloriTime frame: At least 4 weeks after completion of therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.